Clinical Characterisation of Lateral Flow Assays for Detection of COVID-19 Antibodies in a population
rudolf, f.; Kaltenbach, H.-M.; linnik, J.; Ruf, M.-T.; Niederhauser, C.; Nickel, B.; Gygax, D.; Savic, M.
Show abstract
ImportanceSerological assays can help diagnose and determine the rate of SARS-CoV-2 infections in a population. ObjectiveWe characterized and compared 11 different lateral flow assays for their performance in diagnostic or epidemiological settings. Design, Setting, ParticipantsWe used two cohorts to determine the specificity: (i) up to 350 blood donor samples from past influenza seasons and (ii) up to 110 samples which tested PCR negative for SARS-CoV-2 during the first wave of SARS-CoV-2 infections in Switzerland. The sensitivity was determined using up to 370 samples which tested PCR positive for SARS-CoV-2 during the same time and is representative for age distribution and severity. Main OutcomeWe found a single test usable for epidemiological studies in the current low-prevalence setting, all other tests showed lacking sensitivity or specificity for a usage in either epidemiological or diagnostic setting. However, orthogonal testing by combining two tests without common cross-reactivities makes testing in a low-prevalence setting feasible. ResultsNine out of the eleven tests showed specificities below 99%, only five of eleven tests showed sensitivities comparable to established ELISAs, and only one fulfilled both criteria. Contrary to previous results from lab assays, five tests measured an IgM response in >80% of the samples. We found no common cross-reactivities, which allows orthogonal testing schemes for five tests of sufficient sensitivities. Conclusions and RelevanceThis study emphasizes the need for large and diverse negative cohorts when determining specificities, and for diverse and representative positive samples when determining sensitivities of lateral flow assays for SARS-CoV-2 infections. Failure to adhere to statistically relevant sample sizes or cohorts exclusively made up of hospitalised patients fails to accurately capture the performance of these assays in epidemiological settings. Our results allow a rational choice between tests for different use cases.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Evaluation of SARS-CoV-2 Antibody Point of Care Devices in the Laboratory and Clinical Setting 94%
- Evaluation of performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM-IgGCombined Antibody Tests 93%
- Performance Evaluation Of A SARS-COV-2 Rapid Antigentest: Test Performance In The Community In The Netherlands 93%
Similar papers in this journal
- SARS-CoV-2 Antibody Lateral Flow Assay for antibody prevalence studies following vaccine roll out: a Diagnostic Accuracy Study 92%
- Sensitivity of RT-PCR testing of upper respiratory tract samples for SARS-CoV-2 in hospitalised patients: a retrospective cohort study. 91%
- Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel 89%
Similar papers in this journal
- Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel 93%
- Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats 92%
- Dutch participatory surveillance framework for evaluating evolutionary changes on SARS-CoV-2 affecting Rapid Diagnostic Test sensitivity in 2022 - 2023. 91%
Similar papers in this journal
- Screening for SARS-CoV-2 infection in asymptomatic individuals using the Panbio™ COVID-19 Antigen Rapid Test (Abbott) compared to RT-qPCR 93%
- SARS-CoV-2 antibody testing in a UK population: detectable IgG for up to 20 weeks post infection 93%
- Meta-Analysis of Robustness of COVID-19 Diagnostic Kits During Early Pandemic 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.